Top

Published in:

01-05-2012 | Clinical Study - Patient Study

Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions

Authors: Nunung Nur Rahmah, Keiichi Sakai, Kenji Sano, Kazuhiro Hongo

Published in: Journal of Neuro-Oncology | Issue 3/2012

Abstract

Angiogenesis is thought to be involved in the progression of glioma grades, and reversion-inducing cysteine-rich protein with Kazal motifs (RECK) has been said to be involved in maturation of vessels. In this study, we aimed to determine whether high micro-vessel density (MVD) expressed by RECK in glioma tissue is correlated with grades of glioma. We also compared RECK expression with that of the formerly known vessel marker, CD34, and vascular endothelial growth factor (VEGF). RECK, CD34, and VEGF immuno-reactivities of 72 glioma tissues were studied. RECK was seen in microvessels of glioma tissues. CD34 showed a similar pattern to RECK, whereas VEGF showed positive staining in cytoplasm of tumor cells and endothelial cells. Average MVD with RECK was 107.6 microvessels (range 7–290). RECK was positively correlated with grades of glioma. RECK and CD34 also showed a strong correlation (P = 0.001). Higher frequency of VEGF staining was also correlated with higher grade of glioma. This is the first study describing expression of RECK in glioma, and its angiogenesis-related nature may provide a potential therapeutic target for glioma treatment in the future.

Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95:13221–13226PubMedCrossRef

Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789–800PubMedCrossRef

Miki T, Takegami Y, Okawa K, Muraguchi T, Noda M, Takahashi C (2007) The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. J Biol Chem 282:12341–12352PubMedCrossRef

Omura A, Matsuzaki T, Mio K, Ogura T, Yamamoto M, Fujita A, Okawa K, Kitayama H, Takahashi C, Sato C, Noda M (2009) RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem 284:3461–3469PubMedCrossRef

Noda M, Takahashi C (2007) Recklessness as a hallmark of aggressive cancer. Cancer Sci 98:1659–1665PubMedCrossRef

Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, Kim HS, Dass CR, Choong PF (2011) RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer 117(15):3517–3528PubMedCrossRef

Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131–140PubMedCrossRef

Gately S, Soff GA, Brem S (1995) The potential role of basic fibroblast growth factor in the transformation of cultured primary human fetal astrocytes and the proliferation of human glioma (U-87) cells. Neurosurgery 37:723–773 discussion 730–722PubMedCrossRef

Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121–133PubMed

10.

Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848PubMedCrossRef

11.

Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109–120PubMedCrossRef

12.

Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310PubMedCrossRef

13.

Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314PubMedCrossRef

14.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRef

15.

Ribatti D, Vacca A, Dammacco F (1999) The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1:293–302PubMedCrossRef

16.

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248PubMedCrossRef

17.

Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409–415PubMedCrossRef

18.

Chen TC, Hinton DR, Yong VW, Hofman FM (1997) TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J Neuroimmunol 73:155–161PubMedCrossRef

19.

Nico B, Crivellato E, Guidolin D, Annese T, Longo V, Finato N, Vacca A, Ribatti D (2010) Intussusceptive microvascular growth in human glioma. Clin Exp Med 10:93–98PubMedCrossRef

20.

Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17–23PubMedCrossRef

21.

Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F (2009) Microvessel density and area in pituitary microadenomas. Endocr Pathol 20:221–226PubMedCrossRef

22.

Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484PubMedCrossRef

23.

Clark JC, Thomas DM, Choong PF, Dass CR (2007) RECK–a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 26:675–683PubMedCrossRef

24.

Rahmah NN, Sakai K, Nakayama J, Hongo K (2010) Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev 33:167–173 discussion 173PubMedCrossRef

25.

Miki T, Shamma A, Kitajima S, Takegami Y, Noda M, Nakashima Y, Watanabe K, Takahashi C (2010) The ss1-integrin-dependent function of RECK in physiologic and tumor angiogenesis. Mol Cancer Res 8:665–676PubMedCrossRef

26.

Chandana EP, Maeda Y, Ueda A, Kiyonari H, Oshima N, Yamamoto M, Kondo S, Oh J, Takahashi R, Yoshida Y, Kawashima S, Alexander DB, Kitayama H, Takahashi C, Tabata Y, Matsuzaki T, Noda M (2010) Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice. BMC Dev Biol 10:84PubMedCrossRef

27.

Song SY, Son HJ, Nam E, Rhee JC, Park C (2006) Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 42:101–108PubMedCrossRef

Title: Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions
Authors: Nunung Nur Rahmah
Keiichi Sakai
Kenji Sano
Kazuhiro Hongo
Publication date: 01-05-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0778-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Targeting DNA repair and the cell cycle in glioblastoma

Spurious progression in pediatric brain tumors

Stereotactic radiosurgery for primary and metastatic sarcomas involving the spine

Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report

P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells

Erratum to: The genotoxic effect of radiofrequency waves on mouse brain